<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Arrowhead Pharmaceuticals, Inc.

    Arrowhead Pharmaceuticals, Inc.

    Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by si...

    Arrowhead Pharmaceuticals develops medicines th...

    Filing Type:    PU
    Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics Holdings Inc.

    Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of...

    Arcturus Therapeutics is developing portfolio o...

    Filing Type:    PU
    Healthereum LLC

    Healthereum LLC

    The Healthereum Patient Behavior Management platform is a full cycle communication...

    The Healthereum Patient Behavior Management pla...

    Filing Type:    CF
    iRhythm Technologies, Inc.

    iRhythm Technologies, Inc.

    iRhythm is a digital healthcare company redefining the way cardiac arrhythmias are...

    iRhythm is a digital healthcare company redefin...

    Filing Type:    PU
    Astellas Pharma, Inc.

    Astellas Pharma, Inc.

    Astellas Pharma Inc. is a pharmaceutical company committed to the therapeutic fiel...

    Astellas Pharma Inc. is a pharmaceutical compan...

    Filing Type:    PU
    BioTelemetry, Inc.

    BioTelemetry, Inc.

    BioTelemetry, Inc. is the leading remote medical technology company focused on the...

    BioTelemetry, Inc. is the leading remote medica...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Compugen Ltd.

    Compugen Ltd.

    Compugen is a drug discovery company with a unique, broadly applicable, predictive...

    Compugen is a drug discovery company with a uni...

    Filing Type:    PU
    Fate Therapeutics, Inc.

    Fate Therapeutics, Inc.

    We are a biopharmaceutical company dedicated to the development of programmed cell...

    We are a biopharmaceutical company dedicated to...

    Filing Type:    PU
    Atossa Genetics Inc.

    Atossa Genetics Inc.

    Seattle-based Atossa Genetics (NASDAQ: ATOS) is a clinical-stage biopharmaceutical...

    Seattle-based Atossa Genetics (NASDAQ: ATOS) is...

    Filing Type:    PU
    Celcuity Inc.

    Celcuity Inc.

    Celcuity is a cellular analysis company that is discovering new cancer sub-types a...

    Celcuity is a cellular analysis company that is...

    Filing Type:    PU
    Dynavax Technologies Corporation

    Dynavax Technologies Corporation

    Dynavax Technologies Corporation (Nasdaq: DVAX) is a clinical-stage biopharmaceuti...

    Dynavax Technologies Corporation (Nasdaq: DVAX)...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.